4-isopropoxy-3-nitropyridine | 1292369-95-9

• 分子结构分类: 有机化合物 - 有机1,3-偶极化合物 - 烯丙基型1,3-偶极有机化合物
• 英文名称: 4-isopropoxy-3-nitropyridine
• 英文别名: 3-nitro-4-propan-2-yloxypyridine
• CAS: 1292369-95-9
• 化学式: C₈H₁₀N₂O₃
• mdl: MFCD11617884
• 分子量: 182.179
• InChiKey: YJNOHNPTMOMBTR-UHFFFAOYSA-N

物化性质

• 沸点：
  292.4±20.0 °C(Predicted)
• 密度：
  1.199±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.375
• 拓扑面积：
  67.9
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  4-isopropoxy-3-nitropyridine 在 palladium on activated charcoal 、 氢气 、 N,N-二异丙基乙胺 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 18.0h， 生成 2-chloro-N-(4-isopropoxypyridin-3-yl)isonicotinamide
  参考文献：
  名称：

  Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors

  摘要：

  GSK-3 is a serine/threonine kinase that has numerous substrates. Many of these proteins are involved in the regulation of diverse cellular functions, including metabolism, differentiation, proliferation, and apoptosis. Inhibition of GSK-3 may be useful in treating a number of diseases including Alzheimer's disease (AD), type II diabetes, mood disorders, and some cancers, but the approach poses significant challenges. Here, we present a class of isonicotinamides that are potent, highly kinase-selective GSK-3 inhibitors, the members of which demonstrated oral activity in a triple-transgenic mouse model of AD. The remarkably high kinase selectivity and straightforward synthesis of these compounds bode well for their further exploration as tool compounds and therapeutics.

  DOI：

  10.1021/acs.jmedchem.5b01550
• 作为产物：
  描述：

  2-碘代丙烷 、 4-羟基-3-硝基吡啶 在 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 生成 4-isopropoxy-3-nitropyridine
  参考文献：
  名称：

  TRICYCLIC INHIBITORS OF PRO-MATRIX METALLOPROTEINASE ACTIVATION

  摘要：

  本发明涉及三轮车I及其治疗和预防用途，其中变量C1、C2、Z1、Z2、Q、J、R1和R3在规范中定义。治疗和/或预防的疾病包括类风湿性关节炎。

  公开号：

  US20120129811A1

文献信息

• [EN] GSK-3 INHIBITORS<br/>[FR] INHIBITEURS DE GSK-3
  申请人：BRISTOL MYERS SQUIBB CO

  公开号：WO2015069594A1

  公开（公告）日：2015-05-14

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  披露通常涉及到公式I的化合物，包括它们的盐，以及使用这些化合物治疗与GSK-3相关疾病的组合物和方法。
• QUINAZOLINONE-BASED ONCOGENIC-RAS-SELECTIVE LETHAL COMPOUNDS AND THEIR USE
  申请人：THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK

  公开号：US20150175558A1

  公开（公告）日：2015-06-25

  The present invention provides, inter alia, compounds having the structure (1) compositions containing such compounds are also provided. Methods for using such compounds or compositions for treating or ameliorating the effects of a cancer having a cell that harbors an oncogenic RAS mutation, for modulating a lipoxygenase in a ferroptosis cell death pathway, and for depleting reduced glutathione (GSH) in a cell harboring an oncogenic RAS mutation are further provided.

  本发明提供了结构为（1）的化合物，还提供了含有这种化合物的组合物。还提供了使用这种化合物或组合物治疗或改善携带致癌RAS突变细胞的癌症的影响，调节铁死亡细胞途径中的脂氧合酶，以及耗竭携带致癌RAS突变细胞的还原型谷胱甘肽（GSH）的方法。
• GSK-3 INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160272621A1

  公开（公告）日：2016-09-22

  The disclosure generally relates to compounds of formula I, including their salts, as well as compositions and methods of using the compounds to treat disorders associated with GSK-3.

  本发明涉及公式I的化合物及其盐，以及使用这些化合物治疗与GSK-3相关的疾病的组合物和方法。
• US9695133B2
  申请人：——

  公开号：US9695133B2

  公开（公告）日：2017-07-04
• US9718804B2
  申请人：——

  公开号：US9718804B2

  公开（公告）日：2017-08-01